M2 macrophage polarization program (M2 polarization)

M2 macrophage polarization is a complex biological program where macrophages transition into an alternatively activated state, primarily driven by Th2 cytokines such as interleukin-4 (IL-4) and interleukin-13 (IL-13) [1][2]. This program is characterized by high expression of the mannose receptor (CD206), scavenger receptors (CD163), and the enzyme arginase-1, which suppresses pro-inflammatory responses and promotes tissue remodeling [3]. Functionally, M2 macrophages are essential for wound healing and the resolution of inflammation; however, they are frequently hijacked in the tumor microenvironment to support tumor growth, angiogenesis, and immunosuppression [4][5]. In the context of oncology, these cells are often referred to as tumor-associated macrophages (TAMs) that shield the tumor from T-cell-mediated attacks [5]. Therapeutic strategies targeting this program aim to either deplete these cells or reprogram them toward a pro-inflammatory M1 phenotype to restore anti-tumor immunity [6]. Key molecular drivers of this program include the STAT6, IRF4, and PPAR-gamma transcription factors, which serve as potential points of pharmacological intervention [1][4]. Drugs like CSF-1R inhibitors are used to reduce the presence of M2-like macrophages in tumors, while other agents seek to block the signaling pathways that maintain the M2 state [4][6].

Other names

Alternatively activated macrophage polarizationM2 phenotypeM2 macrophage activationAnti-inflammatory macrophage polarization

Modulation of signaling cascades (e.g., JAK/STAT6, PI3K/Akt/mTOR, PPAR-gamma) to inhibit the transition to or maintenance of the M2 phenotype, or to induce reprogramming toward an M1 phenotype.